RxDoctor Payments DataLook up a doctor →

Cesar Plazas-Guzman, MD

Endocrinology, Diabetes & Metabolism · Chesapeake, VANPI 1720407851

Payments from drug & device makers

$13,696in general payments, 2019–2025

Across 630 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Bayer$772
  • AstraZeneca$768
  • Radius Health, Inc.$665
  • plus $7K from 37 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk106$1,842
Lilly USA, LLC92$1,463
Amgen(2 entities)59$1,398
Bayer27$772
AstraZeneca(2 entities)13$768
Radius Health, Inc.27$665
Corcept Therapeutics28$658
Mannkind Corporation29$613
Dexcom, Inc.27$513
Insulet Corporation21$479
Boehringer Ingelheim27$472
Sanofi-aventis U.S. LLC15$330
Xeris Pharmaceuticals, Inc.14$328
Tandem Diabetes Care, Inc.7$310
Medtronic7$308
Abbott14$298
Ascendis Pharma Endocrinology Inc14$216
Amneal Pharmaceuticals LLC11$198
AbbVie11$190
Kyowa Kirin, Inc.8$187
Pfizer9$186
BETA Bionics, Inc.8$180
Recordati_rare_diseases_inc.9$173
Cequr Corporation3$165
Lifescan, Inc.5$155
Merck8$128
IBSA Pharma Inc.4$95
Ultragenyx Pharmaceutical Inc.4$88
Amarin Pharma, Inc.4$77
Sequel Med Tech, LLC2$53
Amphastar Pharmaceuticals, Inc.1$49
Embecta Corp.1$46
Endo USA, Inc.2$45
EUSA Pharma (US) LLC2$45
Zealand Pharma US, Inc.2$36
Tolmar, Inc.2$29
Neurocrine Biosciences, Inc.1$28
Novartis1$22
Amryt Pharma Holdings Ltd1$21
Takeda Pharmaceuticals U.S.A., Inc.1$20
Acella Pharmaceuticals, LLC1$18
Clarus Therapeutics Inc.1$15
Johnson & Johnson1$15

How this compares

$13,696 in reported general payments places this provider in the 85th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia →

Medicare billing

Part B allowed, 2024
$238,884
Medicare patients
533
Services billed
8,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Chesapeake

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →